Cargando…
Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (8...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074605/ https://www.ncbi.nlm.nih.gov/pubmed/8679462 |
_version_ | 1782138002442551296 |
---|---|
author | Terashima, M. Hayashi, K. Fukushima, M. Ide, H. Iizuka, T. Kakegawa, T. Ando, N. Tanaka, O. Shinoda, M. Isono, K. Ishida, K. Ikeuchi, S. Endo, M. Takiyama, W. Yanagawa, T. |
author_facet | Terashima, M. Hayashi, K. Fukushima, M. Ide, H. Iizuka, T. Kakegawa, T. Ando, N. Tanaka, O. Shinoda, M. Isono, K. Ishida, K. Ikeuchi, S. Endo, M. Takiyama, W. Yanagawa, T. |
author_sort | Terashima, M. |
collection | PubMed |
description | A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 10(3) ml-1 well-1) were cultured for 14 days and exposed to drugs on days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. IC90 values against several anti-cancer drugs were determined and population distributions of IC90 for each drug served as the basis for judging sensitivity. The 10th percentiles of IC90 (microgram ml-1) for CDDP, 5-FU, DOX, CPM, MTX, VP16, IFOS, VDS, BLM and CDDP + 5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15 + 0.09 respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer. IMAGES: |
format | Text |
id | pubmed-2074605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20746052009-09-10 Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. Terashima, M. Hayashi, K. Fukushima, M. Ide, H. Iizuka, T. Kakegawa, T. Ando, N. Tanaka, O. Shinoda, M. Isono, K. Ishida, K. Ikeuchi, S. Endo, M. Takiyama, W. Yanagawa, T. Br J Cancer Research Article A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 10(3) ml-1 well-1) were cultured for 14 days and exposed to drugs on days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. IC90 values against several anti-cancer drugs were determined and population distributions of IC90 for each drug served as the basis for judging sensitivity. The 10th percentiles of IC90 (microgram ml-1) for CDDP, 5-FU, DOX, CPM, MTX, VP16, IFOS, VDS, BLM and CDDP + 5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15 + 0.09 respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer. IMAGES: Nature Publishing Group 1996-07 /pmc/articles/PMC2074605/ /pubmed/8679462 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Terashima, M. Hayashi, K. Fukushima, M. Ide, H. Iizuka, T. Kakegawa, T. Ando, N. Tanaka, O. Shinoda, M. Isono, K. Ishida, K. Ikeuchi, S. Endo, M. Takiyama, W. Yanagawa, T. Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title | Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title_full | Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title_fullStr | Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title_full_unstemmed | Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title_short | Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
title_sort | drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074605/ https://www.ncbi.nlm.nih.gov/pubmed/8679462 |
work_keys_str_mv | AT terashimam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT hayashik drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT fukushimam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT ideh drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT iizukat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT kakegawat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT andon drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT tanakao drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT shinodam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT isonok drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT ishidak drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT ikeuchis drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT endom drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT takiyamaw drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem AT yanagawat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem |